Home Cart Sign in  
Chemical Structure| 1028486-01-2 Chemical Structure| 1028486-01-2

Structure of Alisertib
CAS No.: 1028486-01-2

Chemical Structure| 1028486-01-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50 = 1.2 nM) that binds to Aurora A kinase, causing mitotic spindle abnormalities and mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy by targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells, demonstrating antitumor activity.

Synonyms: MLN 8237

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Alisertib

CAS No. :1028486-01-2
Formula : C27H20ClFN4O4
M.W : 518.92
SMILES Code : O=C(O)C1=CC=C(NC2=NC=C3C(C4=CC=C(Cl)C=C4C(C5=C(OC)C=CC=C5F)=NC3)=N2)C=C1OC
Synonyms :
MLN 8237
MDL No. :MFCD16621243
InChI Key :ZLHFILGSQDJULK-UHFFFAOYSA-N
Pubchem ID :24771867

Safety of Alisertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Alisertib

epigenetics
DNA

Isoform Comparison

Biological Activity

Target
  • Aurora A

    Aurora A, IC50:1.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
GB169 neurosphere cells 200 nM 12 days Induced apoptosis and senescence, reduced tumor cell proliferation PMC4528677
GB30 neurosphere cells 200 nM 12 days Induced apoptosis and senescence, reduced tumor cell proliferation PMC4528677
GB9 neurosphere cells 200 nM 12 days Induced apoptosis and senescence, reduced tumor cell proliferation PMC4528677
ROSAKIT D816V cells 500 nM 24 h To evaluate the induction of apoptosis by Alisertib in ROSAKIT D816V cells, results showed that Alisertib significantly induced apoptosis at submicromolar doses. PMC9999558
HMC-1 cells 500 nM 24 h To evaluate the induction of apoptosis by Alisertib in HMC-1 cells, results showed that Alisertib significantly induced apoptosis at submicromolar doses. PMC9999558
CAMA-1 200 nM 72 h To investigate the cytotoxic effect of Alisertib on RB-deficient cells, results showed that RB-deficient cells were more sensitive to Alisertib, leading to apoptosis. PMC10680093
T47D 200 nM 72 h To investigate the cytotoxic effect of Alisertib on RB-deficient cells, results showed that RB-deficient cells were more sensitive to Alisertib, leading to apoptosis. PMC10680093
MCF7 200 nM 72 h To investigate the cytotoxic effect of Alisertib on RB-deficient cells, results showed that RB-deficient cells were more sensitive to Alisertib, leading to apoptosis. PMC10680093
A549 lung cancer cells 500 nM 7 days Induced cellular senescence, enhanced SA-β-gal activity, and inhibited clonogenic capacity PMC9460569
Hs294T cells 1 μM 3 days Investigated the effect of Alisertib on DNA damage, finding that Alisertib increased the expression of the DNA damage marker γH2AX. PMC5652019
SK-Mel5 cells 1 μM 3 days Investigated the effect of Alisertib on DNA damage, finding that Alisertib increased the expression of the DNA damage marker γH2AX. PMC5652019
DLD-1 0.05 µM, 0.1 µM, 0.2 µM 72 h To evaluate the anti-proliferative effects of Alisertib and TAK-733 alone and in combination, it was found that the combination showed stronger synergistic effects in KRAS/PIK3CA double-mutant cell lines. PMC4468631
HCT116 0.05 µM, 0.1 µM, 0.2 µM 72 h To evaluate the anti-proliferative effects of Alisertib and TAK-733 alone and in combination, it was found that the combination showed stronger synergistic effects in KRAS/PIK3CA double-mutant cell lines. PMC4468631
BCL cell lines (LY10, SU-DHL6, LY7, Jeko-1) 10 to 1000 nM 72 h To evaluate the cytotoxic effect of Alisertib in BCL cell lines, results showed concentration-dependent cytotoxicity in BCL cell lines. PMC4581881
TCL cell lines (C5MJ, DND41, H9, HH) 10 to 1000 nM 72 h To evaluate the cytotoxic effect of Alisertib in TCL cell lines, results showed concentration-dependent cytotoxicity in TCL cell lines. PMC4581881
MDA-MB-231 cells 100 nM 2 h To investigate the effect of Alisertib on the ATP/ADP ratio in mitotic cells, results showed that Alisertib treatment significantly reduced the ATP/ADP ratio. PMC8484571
MDA-MB-231 cells 100 nM 6 h To investigate the effect of Alisertib on oxidative phosphorylation (OXPHOS) in cells, results showed that Alisertib treatment significantly reduced intracellular ATP levels. PMC8484571

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MCF7 xenograft model Oral 10 mg/kg 6 days a week for 3 weeks To evaluate the therapeutic effect of Alisertib on RB-deficient tumors in vivo, results showed that Alisertib significantly inhibited the growth of RB-deficient tumors. PMC10680093
Nude mice Intracranial GB neurosphere xenograft model Oral 20 mg/kg Twice daily, 5 days/week for 2 weeks Extended median survival of mice, reduced tumor cell proliferation PMC4528677
Mice MYC-driven SCLC mouse model Oral gavage 20 mg/kg 5 days on, 2 days off weekly, continuous treatment To evaluate the effect of Alisertib in combination with CHK1 inhibitor Prexasertib on the survival of MYC-driven SCLC mouse model, results showed that the combination therapy significantly prolonged the survival of mice. PMC6677768
Nude mice Hs294T xenograft model Subcutaneous injection 30 mg/kg Once daily for 3 weeks Investigated the effect of Alisertib on tumor growth, finding that Alisertib significantly inhibited tumor growth. PMC5652019
Nude mice Colorectal cancer cell line xenograft models Oral 3 mg/kg Once daily for 22 days To evaluate the anti-tumor activity of Alisertib and TAK-733 alone and in combination in colorectal cancer cell line xenograft models, it was found that the combination showed synergistic effects in the HCT116 xenograft model. PMC4468631
SCID mice TCL xenograft model Alisertib oral, Romidepsin intraperitoneal 20 mg/kg Alisertib daily for 21 days; Romidepsin on days 1, 9, 16 To evaluate the synergistic effect of Alisertib and Romidepsin combination therapy in a TCL xenograft model, results showed significant tumor growth inhibition and improved survival. PMC4581881
BALB/c mice 4T1 xenograft model Oral 15 mg/kg Once daily for 17 days To investigate the tumor suppressive effect of Alisertib in combination with metformin, results showed that the combination treatment significantly inhibited tumor growth. PMC8484571

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02551055 Neoplasms, Advanced or Metasta... More >>tic Less << Phase 1 Terminated(Business Decision; ... More >>No Safety Or Efficacy Concerns.) Less << - United States, New York ... More >> Lake Success, New York, United States New York, New York, United States United States, Pennsylvania Philadelphia, Pennsylvania, United States United States, Texas Dallas, Texas, United States Houston, Texas, United States Spain Barcelona, Spain Less <<
NCT01540682 Head and Neck Cancer Phase 1 Completed - United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT01316692 Recurrent Melanoma ... More >> Stage IIIc Melanoma Stage IV Melanoma Less << Phase 2 Terminated(low accrual) - United States, Tennessee ... More >> Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 Less <<
NCT01316692 - Terminated(low accrual) - -
NCT01677559 Adenocarcinoma ... More >> Pancreatic Neoplasms Less << Phase 1 Completed - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT02327169 Advanced Nonhematologic Malign... More >>ancies Less << Phase 1 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 2114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 2115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 2115 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Texas The University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 France Institut Bergonie Bordeaux cedex, Gironde, France, 33076 Institut Claudius Regaud-Oncopole Toulouse cedex 09, Haute Garonne, France, 31059 Institut Gustave Roussy Villejuif cedex, Val De Marne, France, 94805 Spain Hospital Universitari Vall d'Hebron Barcelona, Spain, 8035 START Madrid. Fundacion Jimenez Diaz Madrid, Spain, 28040 Hospital Clinico Universitario Virgen de la Victoria Malaga, Spain, 29010 United Kingdom Sarah Cannon Research Institure UK London, Greater London, United Kingdom, W1G 6AD The Chrisie Manchester, Greater Manchester, United Kingdom, M20 4BX Churchill Hospital Oxford, Oxfordshire, United Kingdom, OX3 7LJ Less <<
NCT02780011 CD30-positive Lymphoma ... More >> CD30-positive Solid Tumor Less << Phase 1 Withdrawn(lack of funding) September 2018 United States, Texas ... More >> Houston Methodist Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01397825 Diffuse Large B-Cell Lymphoma ... More >> Transformed Follicular Lymphoma Mantle Cell Lymphoma Burkitt's Lymphoma Less << Phase 1 Phase 2 Completed - -
NCT01601535 Neuroblastoma Phase 1 Phase 2 Active, not recruiting December 2018 United States, California ... More >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027-0700 Lucile Packard Children's Hospital at Stanford University Medical Center Palo Alto, California, United States, 94304 UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, Colorado Children Hospital of Colorado Aurora, Colorado, United States, 80045 United States, Georgia Children's Healthcare of Atlanta Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Comer Children's Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Childrens Hospital Boston, Dana-Farber Cancer Institute. Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 United States, Texas Cook Children's Medical Center - Fort Worth Fort Worth, Texas, United States, 76104 United States, Washington Children's Hospital and Regional Medical Center - Seattle Seattle, Washington, United States, 98105 Canada, Ontario Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Less <<
NCT01034553 - Completed - -
NCT01397825 - Completed - -
NCT00500903 Advanced Malignancies PHASE1 COMPLETED 2011-02-23 Sarah Cannon Research Institut... More >>e (SCRI), Nashville, Tennessee, 37203, United States Less <<
NCT00962091 Advanced Solid Tumors PHASE1 COMPLETED 2014-07-01 Premiere Oncology, A Medical C... More >>orporation, Santa Monica, California, 90404, United States Less <<
NCT01034553 Refractory Multiple Myeloma Phase 1 Phase 2 Completed - United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, California University of California, San Francisco San Fransisco, California, United States, 94143 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 Less <<
NCT01154816 Hepatoblastoma ... More >> Previously Treated Childhood Rhabdomyosarcoma Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Kidney Neoplasm Recurrent Childhood Malignant Germ Cell Tumor Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Soft Tissue Sarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Neuroblastoma Recurrent Osteosarcoma Less << Phase 2 Completed - -
NCT01094288 Advanced Solid Tumors ... More >> Adenocarcinoma of the Prostate Less << Phase 1 Completed - United States, Indiana ... More >> Indianapolis, Indiana, United States United States, Oregon Portland, Oregon, United States United States, Texas San Antonio, Texas, United States United States, Washington Seattle, Washington, United States Less <<
NCT01482962 Relapsed Peripheral T-Cell Lym... More >>phoma Refractory Peripheral T-Cell Lymphoma Less << Phase 3 Completed - -
NCT01154816 - Completed - -
NCT00651664 Advanced Malignancies Phase 1 Completed - Spain ... More >> Ciutat Sanitaria Vall d'Hebron - Servicio de Oncologia Barcelona, Spain, 08035 H. Clínico Universitario de Valencia Valencia, Spain Less <<
NCT02560025 Acute Myeloid Leukemia Phase 2 Active, not recruiting October 2019 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT02114229 Malignant Rhabdoid Tumor ... More >> Atypical Teratoid Rhabdoid Tumor Less << Phase 2 Recruiting May 2027 United States, California ... More >> Children's Hospital of Los Angeles Withdrawn Los Angeles, California, United States, 90027 Lucille Packard Children's Hospital at Stanford University Medical Center Recruiting Palo Alto, California, United States, 94304 Contact: Sonia Partap, MD    650-723-0993    spartap@stanford.edu    Principal Investigator: Sonia Partap, MD          Rady Children's Hospital Recruiting San Diego, California, United States, 92123 Contact: John Crawford, MD, MS    858-576-1700    jcrawford@rchsd.org    Principal Investigator: John Crawford, MD, MS          United States, Colorado Children's Hospital Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Kathleen Dorris, MD    720-777-6672    kathleen.dorris@childrenscolorado.org    Principal Investigator: Kathleen Dorris, MD          United States, District of Columbia Children's National Medical Center Recruiting Washington, District of Columbia, United States, 20010 Contact: Lindsay B. Kilburn, MD    202-476-2800    lkilburn@childrensnational.org    Principal Investigator: Lindsay B. Kilburn, MD          United States, Florida UF Cancer Center at Orlando Health Recruiting Orlando, Florida, United States, 32806 Contact: Amy A. Smith, MD    321-841-7246    amy.smith@orlandohealth.com    Principal Investigator: Amy A. Smith, MD          United States, Georgia Children's Healthcare of Atlanta Recruiting Atlanta, Georgia, United States, 30322 Contact: Sindy Moon    404-785-1441    cindy.moon@choa.org    Contact: Jaclyn Smith    404-785-0692    jaclyn.smith@choa.org    Principal Investigator: Dolly Aguilera, MD          United States, Minnesota Children's Hospital and Clinics of Minnesota Recruiting Minneapolis, Minnesota, United States, 55102 Contact: Anne Bendel, MD    651-220-6732    anne.bendel@childrensmn.org    Principal Investigator: Anne Bendel, MD          United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Tabatha E. Doyle, RN    901-595-2544    tabatha.doyle@stjude.org    Principal Investigator: Santhosh Upadhyaya, MD          United States, Texas Texas Children's Hospital Recruiting Houston, Texas, United States, 77030 Contact: Patricia Baxter, MD    832-824-1000    pabaxter@txch.org    Principal Investigator: Patricia Baxter, MD          United States, Washington Seattle Children's Hospital Recruiting Seattle, Washington, United States, 98105 Contact: Sarah Leary, MD    866-987-2000    sarah.leary@seattlechildrens.org    Principal Investigator: Sarah Leary, MD Less <<
NCT01897012 MYC Positive ... More >>Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Recurrent Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Burkitt Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Refractory Hodgkin Lymphoma Refractory Mantle Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Less << Phase 1 Active, not recruiting - United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03005262 - - - -
NCT02560025 - Active, not recruiting - -
NCT02038647 Small Cell Lung Cancer (SCLC) Phase 2 Active, not recruiting August 7, 2017 -
NCT01471964 Non-small Cell Lung Cancer Met... More >>astatic Non-small Cell Lung Cancer Recurrent Less << Phase 1 Phase 2 Terminated(Phase I portion com... More >>pleted. Phase II will open pending amendment approval.) Less << - United States, Pennsylvania ... More >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT01482962 - Completed - -
NCT01695941 Recurrent B-Cell Non-Hodgkin L... More >>ymphoma Recurrent Mantle Cell Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Mantle Cell Lymphoma Less << Phase 1 Active, not recruiting - United States, New York ... More >> Montefiore Medical Center-Einstein Campus Bronx, New York, United States, 10461 Montefiore Medical Center - Moses Campus Bronx, New York, United States, 10467 Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York, United States, 10016 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT02367352 Advanced Solid Tumors ... More >> Ovarian Cancer Small Cell Lung Cancer Less << Phase 1 Completed - Japan ... More >> Chiba, Japan Shizuoka, Japan Korea, Republic of Seoul, Korea, Republic of Less <<
NCT01923337 Mucinous Adenocarcinoma of the... More >> Colon Mucinous Adenocarcinoma of the Rectum Recurrent Colon Cancer Recurrent Rectal Cancer Signet Ring Adenocarcinoma of the Colon Signet Ring Adenocarcinoma of the Rectum Stage IIIA Colon Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Active, not recruiting December 2019 United States, California ... More >> UC Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 Less <<
NCT02444884 Unspecified Childhood Solid Tu... More >>mor, Excluding CNS Neuroblastoma Less << Phase 1 Completed - -
NCT01924260 Acinar Cell Adenocarcinoma of ... More >>the Pancreas Duct Cell Adenocarcinoma of the Pancreas Recurrent Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Active, not recruiting December 2020 United States, California ... More >> UC Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 Less <<
NCT01466881 Adult Nasal Type Extranodal NK... More >>/T-Cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Hepatosplenic T-Cell Lymphoma Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Recurrent Adult Non-Hodgkin Lymphoma Recurrent Adult T-Cell Leukemia/Lymphoma Less << Phase 2 Completed - -
NCT01045421 - Completed - -
NCT01637961 Recurrent Uterine Corpus Sarco... More >>ma Uterine Corpus Leiomyosarcoma Less << Phase 2 Completed - -
NCT01637961 - Completed - -
NCT01466881 - Completed - -
NCT01799278 Small Cell Prostate Cancer ... More >> Neuroendocrine Prostate Cancer Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers Less << Phase 2 Completed - United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Weill Cornell Medical College New York, New York, United States, 10065 United States, North Carolina Duke University Health System Durham, North Carolina, United States, 27710 United States, Ohio University Hospitals Cleveland Medical Center Cleveland, Ohio, United States, 44106 United States, Washington University of Washington Medical Center Seattle, Washington, United States, 98195 Less <<
NCT01653028 - Completed - -
NCT00697346 B-cell Follicular Lymphoma|B-c... More >>ell Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|B-cell Mantle Cell Lymphoma|B-cell Small Lymphocytic Lymphoma|B-Cell Chronic Lymphocytic Leukemia|Multiple Myeloma|Waldenstrom's Macroglobulinemia|Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Enteropathy Associated T-cell Lymphoma|NK Lymphoma Less << PHASE1 COMPLETED 2016-10-19 Scottsdale, Arizona, United St... More >>ates|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|Buffalo, New York, United States|Chapel Hill, North Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States Less <<
NCT01091428 Ovarian Carcinoma ... More >> Fallopian Tube Cancer Peritoneal Cancer Breast Carcinoma Less << Phase 2 Completed - United States, New York ... More >> Bronx, New York, United States United States, Pennsylvania Philadelphia, Pennsylvania, United States United States, Texas Houston, Texas, United States United States, Washington Seattle, Washington, United States Less <<
NCT02319018 Malignant Digestive System Neo... More >>plasm Less << Phase 1 Completed - United States, Connecticut ... More >> Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States, 06510 Yale University New Haven, Connecticut, United States, 06520 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 Less <<
NCT01045421 Advanced Nonhematological Mali... More >>gnancies Non-Small Cell Lung Cancer Small Cell Lung Cancer Metastatic Breast Cancer Head and Neck Squamous Cell Carcinoma Gastroesophageal Adenocarcinoma Less << Phase 1 Phase 2 Completed - United States, Texas ... More >> Houston, Texas, United States United States, Utah Salt Lake City, Utah, United States Less <<
NCT01639911 Malignant Neoplasm of Breast ... More >> CNS Malignancy Malignant Neoplasm of Gastrointestinal Tract Genitourinary Neoplasms Malignancy and Gender Unspecified Head and Neck Neoplasms Melanoma Malignant Neoplasm of Thorax Less << Phase 1 Completed - United States, Illinois ... More >> University of Illinois Cancer Center Chicago, Illinois, United States, 60612 Less <<
NCT01653028 Myxofibrosarcoma ... More >> Recurrent Adult Soft Tissue Sarcoma Recurrent Leiomyosarcoma Recurrent Liposarcoma Recurrent Malignant Peripheral Nerve Sheath Tumor Recurrent Undifferentiated Pleomorphic Sarcoma Stage III Soft Tissue Sarcoma AJCC v7 Stage IV Soft Tissue Sarcoma AJCC v7 Less << Phase 2 Completed - -
NCT00853307 Ovarian Carcinoma PHASE2 COMPLETED 2011-01-27 Summit Medical Group, Berkeley... More >> Heights, New Jersey, 07922, United States Less <<
NCT00853307 Ovarian Carcinoma PHASE2 COMPLETED 2011-01-27 Summit Medical Group, Berkeley... More >> Heights, New Jersey, 07922, United States Less <<
NCT01567709 Adult B Acute Lymphoblastic Le... More >>ukemia Adult T Acute Lymphoblastic Leukemia Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Chronic Lymphocytic Leukemia Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Hepatosplenic T-Cell Lymphoma Intraocular Lymphoma Lymphomatous Involvement of Non-Cutaneous Extranodal Site Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Nodal Marginal Zone Lymphoma Primary Cutaneous B-Cell Non-Hodgkin Lymphoma Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-Cell Leukemia/Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides and Sezary Syndrome Recurrent Non-Hodgkin Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hairy Cell Leukemia Small Intestinal Lymphoma Splenic Marginal Zone Lymphoma T-Cell Large Granular Lymphocyte Leukemia Testicular Lymphoma Waldenstrom Macroglobulinemia Less << Phase 1 Completed - United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT01091428 - Completed - -
NCT01799278 - Completed - -
NCT00830518 Acute Myelogenous Leukemia|Hig... More >>h-Grade Myelodysplastic Syndrome Less << PHASE2 COMPLETED 2011-07-04 Hematology and Oncology Associ... More >>ates of Northern New Jersey, Morristown, New Jersey, 07962, United States Less <<
NCT02187991 Breast Cancer ... More >> Breast Carcinoma Breast Tumors Malignant Neoplasm of Breast Less << Phase 2 Active, not recruiting September 2019 United States, Texas ... More >> 22 Sites Including Dallas And Austin, Texas, United States Less <<
NCT01848067 Adenocarcinoma of the Prostate... More >> Hormone-resistant Prostate Cancer Recurrent Prostate Cancer Stage IV Prostate Cancer Less << Phase 1 Phase 2 Completed - United States, Pennsylvania ... More >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT01848067 - Completed - -
NCT01779843 Acute Myelogenous Leukemia Phase 1 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT00830518 Acute Myelogenous Leukemia|Hig... More >>h-Grade Myelodysplastic Syndrome Less << PHASE2 COMPLETED 2011-07-04 Hematology and Oncology Associ... More >>ates of Northern New Jersey, Morristown, New Jersey, 07962, United States Less <<
NCT02219789 Estrogen Receptor Positive ... More >> Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Less << Phase 1 Completed - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT01812005 - Terminated(Slow patient enroll... More >>ment and study discontinued after 14 patients enrolled) Less << - -
NCT01812005 Extranodal Marginal Zone B-cel... More >>l Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Splenic Marginal Zone Lymphoma Waldenstr?m Macroglobulinemia Less << Phase 2 Terminated(Slow patient enroll... More >>ment and study discontinued after 14 patients enrolled) Less << - United States, Georgia ... More >> Emory University Atlanta, Georgia, United States, 30322 United States, Ohio Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT02860000 Estrogen Receptor Status ... More >> HER2/Neu Negative Invasive Breast Carcinoma Postmenopausal Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Less << Phase 2 Recruiting December 15, 2021 United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office    855-776-0015       Principal Investigator: Tufia C. Haddad Less <<
NCT00807495 Diffuse Large B-cell Lymphoma|... More >>Mantle Cell Lymphoma|Burkitt's Lymphoma|T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma|Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component Less << PHASE2 COMPLETED 2013-02-13 Hematology Oncology Associates... More >>, Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, 08060, United States Less <<
NCT00807495 Diffuse Large B-cell Lymphoma|... More >>Mantle Cell Lymphoma|Burkitt's Lymphoma|T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma|Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component Less << PHASE2 COMPLETED 2013-02-13 Hematology Oncology Associates... More >>, Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, 08060, United States Less <<
NCT02259010 Advanced Solid Tumors ... More >> Relapsed/Refractory Lymphoma Less << Phase 1 Unknown April 2016 United States, Missouri ... More >> St. Louis, Missouri, United States United States, Oklahoma Oklahoma City, Oklahoma, United States United States, Tennessee Germantown, Tennessee, United States United States, Texas Dallas, Texas, United States Less <<
NCT01613261 Advanced Nonhematologic Malign... More >>ancies Less << Phase 1 Withdrawn November 2015 United States, Texas ... More >> South Texas Accelerated Research Therapeutics (START) San Antonio, Texas, United States, 78229 Less <<
NCT02109328 Bladder Cancer ... More >> Transitional Cell Carcinoma Less << Phase 2 Unknown March 2018 Italy ... More >> Fondazione IRCCS Istituto Nazionale dei Tumori Not yet recruiting Milano, Mi, Italy, 20133 Contact: Andrea Necchi, MD    +39022390 ext 2402    andrea.necchi@istitutotumori.mi.it    Sub-Investigator: Patrizia Giannatempo, MD          Principal Investigator: Andrea Necchi, MD Less <<
NCT02530619 Acute Megakaryoblastic Leukemi... More >>a Myelofibrosis Primary Myelofibrosis Less << Not Applicable Active, not recruiting March 2020 United States, Florida ... More >> University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States, 33136 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT01844583 Solid Tumors ... More >>Lymphoma Less << Phase 1 Completed - United States, Florida ... More >> Sarasota, Florida, United States United States, Missouri St. Louis, Missouri, United States United States, Oklahoma Oklahoma City, Oklahoma, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Dallas, Texas, United States San Antonio, Texas, United States Less <<
NCT02293005 Lung Cancer|Mesothelioma PHASE2 COMPLETED 2021-07-06 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01512758 Advanced Solid Tumors|Lymphoma... More >>s Less << PHASE1 COMPLETED 2013-10-08 National Cancer Centre, Tiong ... More >>Bahru, 169610, Singapore Less <<
NCT02700022 Diffuse Large B-cell Lymphoma|... More >>Follicular Lymphoma|Burkitt Lymphoma Less << PHASE1 TERMINATED 2017-08-18 City of Hope Comprehensive Can... More >>cer Center, Duarte, California, 91010, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hills, North Carolina, 27599, United States Less <<
NCT01898078 Advanced Solid Tumors|Lymphoma PHASE1 COMPLETED 2017-01-24 Bronx, New York, United States... More >>|Nashville, Tennessee, United States|San Antonio, Texas, United States Less <<
NCT02186509 Adult Anaplastic Astrocytoma ... More >> Adult Anaplastic Ependymoma Adult Anaplastic Oligodendroglioma Adult Brain Stem Glioma Adult Diffuse Astrocytoma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Adult Oligodendroglioma Adult Pilocytic Astrocytoma Adult Pineal Gland Astrocytoma Adult Subependymal Giant Cell Astrocytoma Recurrent Adult Brain Tumor Less << Phase 1 Active, not recruiting January 2019 United States, Pennsylvania ... More >> Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT02719691 Metastatic Breast Cancer ... More >> Solid Tumors Less << Phase 1 Recruiting November 2018 United States, Colorado ... More >> University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Matthew Lee    303-848-0630    matthew.lee@ucdenver.edu    Principal Investigator: Jennifer Diamond, MD Less <<
NCT02214147 Advanced Solid Tumors|Relapsed... More >>/Refractory Lymphoma Less << PHASE1 COMPLETED 2016-07-18 Miami, Florida, United States|... More >>Chicago, Illinois, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States Less <<
NCT02214147 Advanced Solid Tumors|Relapsed... More >>/Refractory Lymphoma Less << PHASE1 COMPLETED 2016-07-18 Miami, Florida, United States|... More >>Chicago, Illinois, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States Less <<
NCT02812056 Malignant Neoplasms of Digesti... More >>ve Organs Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Lip Oral Cavity and Pharynx Malignant Neoplasms of Male Genital Organs Less << Phase 1 Withdrawn - -
NCT01714947 Advanced Solid Tumors ... More >> Lymphoma Less << Phase 1 Completed - United States, Washington ... More >> Comprehensive Clinical Development Tacoma, Washington, United States, 98418 Less <<
NCT01714947 - Completed - -
NCT06095505 Small Cell Lung Cancer PHASE2 RECRUITING 2026-01-31 Southern Cancer Center, Daphne... More >>, Alabama, 36526, United States|The Oncology Institute of Hope and Innovation, Long Beach, California, 90805, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, 80124, United States|Georgetown Lombardi Cancer Center, Washington, District of Columbia, 20057, United States|The Oncology Institute of Hope and Innovation, Fort Lauderdale, Florida, 33316, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Illinois Cancer Specialists, Niles, Illinois, 60714, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Minnesota Oncology Hematology, Burnsville, Minnesota, 55337, United States|Oncology Hematology Care Clinical Trials, Cincinnati, Ohio, 45226, United States|University Hospital - Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Zangmeister Cancer Center, Columbus, Ohio, 43219, United States|Oncology Associates of Oregon, Eugene, Oregon, 97401, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, 29425, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Oncology & Hematology Associates of Southwest Virginia, Blacksburg, Virginia, 24073, United States|Universtity of Virginia Health System, Charlottesville, Virginia, 22908, United States|Virginia Cancer Specialists Research Institute, Fairfax, Virginia, 22031, United States|Northwest Cancer Specialists, Vancouver, Washington, 98686, United States|Marshfield Medical Center, Marshfield, Wisconsin, 54449, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.93mL

0.39mL

0.19mL

9.64mL

1.93mL

0.96mL

19.27mL

3.85mL

1.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories